跳至主要内容
临床试验/NCT00660803
NCT00660803已完成不适用

Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer

AstraZeneca1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2008年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
200
试验地点
1
主要终点
Time to tumour progression

研究概览

简要总结

Characterize the demographic and clinical features, as well as the main treatment results, among patients with advanced breast cancer treated with fulvestrant in Brazil.

研究设计

研究类型
Observational
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Positive HR or ER by immunohistochemistry
  • Postmenopausal status at the time of treatment with fulvestrant
  • Failure of at least one previous endocrine therapy before treatment with fulvestrant.

排除标准

  • Patients who are still undergoing treatment with fulvestrant will not be eligible to participate in the study

研究组 & 干预措施

1

Postmenopausal women with hormone-receptor positive, advanced breast cancer who have failed at least one previous endocrine therapy and who have been treated at any one of the participating centres with fulvestrant.

干预措施: Fulvestrant (Drug)

结局指标

主要结局

Time to tumour progression

Objective response

次要结局

  • Duration of treatment with fulvestrant
  • Time and duration of response
  • Overall survival

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验